Thank you welcome very much all. and to
Pharmaceuticals. the Lisa and Napo wholly President CEO Health and name States you our As Founder, just in subsidiary of my Conte and the is I'm heard, owned Jaguar United
Europe, XXXX of the particular corporation established for focused disorders. we Therapeutics, also use expanding which Crofelemer Napo we rare and Sometimes Italy Milan, the I'm in names to interchangeably. access Napo in on is in a of member Board Jaguar in
value generation you transformative going expect for shareholders. we and shortly of will including stakeholders will in in key be XXXX by our begin today highlight we patients I'm events terms to know letting the that all
theme Moving towards will late-stage opportunities hear infused pipeline revenue-generating important today's this throughout is that you an reality, call.
the December I of Right revenue ended $XX.X review the XX, of $X.X XXXX. year for million XXXX, XXXX year net December increase the approximately results million versus will previous was for XXX.X%. now, fourth XX, top approximately key Prescription quarter for the product ended an line
our and, We I are diarrhea drug business relatively a of market quite means opportunity. often currently from indication typically small HIV-related trajectory to with Mytesi market which current pleased the as approved often say, growth the limited specialty is prescription of specialty
morning, the Regarding events the of I million, approximately this of XX-K just had the cash days couple asked report subsequent annual year about. XXXX, of on XXXX. to our the Form XX-K repeat approximately company's position, $XX.X Jaguar's speak company date for cash $XX.X important March filing that. as meaningful ago, that of as filing in and a of million I'm Cash going an often I'm XX,
initiatives chemotherapy-induced Canalevia-CAX, for treatment to and our the community on Wendt, Following key And Financial Jaguar's we'll hear a Chief results prescription commercial for continue updates commercial educate Jaguar's financial and my efforts in about Carol to Officer, Ian provide the update, Officer. for XXXX. speak will Mytesi-related the from of recap ongoing Lizak, will underway serve then dogs. Ian drug HIV to Commercial Chief of diarrhea
therapy. AIDS diarrhea, of The a is with on the the It's symptomatic adult United our is named Mytesi. Crofelemer. first-in-class reminder, initially the noninfectious name indication drug specifically human HIV-related generic antisecretory specialty relief patients States in in agent approved a of very As for commercialized product HIV anti-retroviral diarrhea
Crofelemer. fast-tracked market. This approved HIV why diarrhea that's first it's relatively by I a the for is the And small mentioned, indication indication As was FDA.
it that state, within a I'm our frequently I milestones. pipeline is going clinical to is about Crofelemer are on a really key focus As what today And is what product. powerful
in product, of are support trial same as trial already benefiting This with of for to our and transformative for revenue benefiting, in results the dose the this United patient commercialized we cancer our I same believe trial, may indications significant States potentially that and what with same Phase conducted HIV-related is product events of OnTarget called the clinical XXXX development year, diarrhea, formulation. of Crofelemer ongoing formulation therapy-related being pipeline the dose, company same Again, the trial program. potential refer tangible and important diarrhea is in pivotal of III CTD opportunities; shareholder, OnTarget generating trial, Crofelemer flagship Mytesi two, the product, stakeholder course, our from
of that the novel potential OnTarget in chloride a Crofelemer's aims to of HIV effectiveness of is with the two in trail or tract patients evaluating of modulation study expand of the substantially the action, ion Diarrhea gastrointestinal CTD diarrhea. mechanism a to setting. related channels the to is mitigate cancer needs in prophylactic reduce blockbuster It indication current limited therapy-related Mytesi the prophylaxis approved from The
expand to accelerated enrollment. past active and trial the new Eastern as in Taiwan in Europe the in year and Republic patient international trial now over to the have sites Georgia both of efforts well Argentina OnTarget as with U.S. Serbia significantly Our and sites
diarrhea. be patients common at will most trial of around OnTarget Jaguar. at XX complete and trial feel XXX% is in patients with is value expected enrollment now as early do Diarrhea is for at OnTarget quarter. which to the cancer essentially quarter second value the the XX%. transformative literally as effects We recognition associated therapy; is many side of XXXX approximately Enrollment over of XXX the just experienced that of
addressing is stopping patient approximately need changing with their to paradigm of which biological comfort cancer approach. a dignity diarrhea, so important, XX% to patients and for due or a addition medical is unmet In therapy life-saving clear shifting focused there
that proven Remember, a patient's placebo-controlled diarrhea. CTD. outcomes a better associated chronic Crofelemer on treatment. cancer required in ability expectation costs, the both cancer at therapies the from provide impacts overall opportunity their for doses Our as providing for cancer remain And diarrhea CTD addressing rehydration for implications trial and of health to and/or chronic, their OnTarget paradigm prophylaxis reduces management is has that targeted targeted and that severe will such evidence regimens, care therapy hospitalization with shift of potential is
For unapproved which such inappropriate which there untested are totally primarily no current antimotility Imodium risks which loperamide drugs tested as chronic are constipating approved or agents again, is administration. which and, and for for and opioids have antidiarrheal
which not now associated an in outpatient with the patients years United cancer type is in used clinic than an radiation curative risk basis, on diarrhea the not Crofelemer that is opioid most to X situations. part the CDC, chemotherapy months and or the chronic Treatment and rest oncology States. which for that the last patient's in of for a metastatic the induces million both that Crofelemer often more have by targeted does there according about Each year, therapies, for can of the constipating opioids. to of life, normalizes. mechanism These are XX work secretory received
we've during how Again, mile to hospital, is mild therapy prevent patients been not OnTarget and CTD This onset in targeted has targeted a perhaps a you it of about tells cause the even impact which clinical the that the a drugs. shutdown have is contributed bowel in that treatment all diarrhea with cancer important prophylactic manufacturers bad cancer with loss studied who of and control to death put flu, experienced is a study organ diarrhea agent meal. trials. is invariably some the in can patients lot
And at Crofelemer the would projected XXXX, CTD, which billion by potential since -- out projections the for drugs. a for nausea market and the proprietary vomiting are analogous an approved days used firm, CINV these about CINV we be to research lowers financial Health reach to be of we're market Well, published generic guidance and and agents opportunity X typically chemotherapy-induced projections for somewhat looking for look chemotherapy global to by market, what don't like first X specific project financial indication, report only $X.X can financial global agents in traditional -- many value of market. the Analyst. are To according drug cytotoxic first is to to the Care the forecast, put this
talking persist years. That's chronic paradigm for the shift. or a we on months With are basis can CTD, that diarrhea about
our as I program, which, are pivotal the excited of Will for drug mentioned, completion application We -- expect CTD successful drug about year We of currently the the in Mytesi. lead then is trial OnTarget same very Crofelemer a as filing to the readout primary targeted new early the of patient in and XXXX. enrollment quarter supplemental for formulation in endpoint to of commercialized a QX second this
completed in line pharmacies final in to steps chain HIV prescribed with with basis business has our from And their engage the chronic forest with compliant applications distribution spent in of are and and bringing in regulatory and/or extensive are support communication FDA it the is safety Mytesi place and common States. new manufacturing rain supply FDA living approved for a most United across use that from network already reminder, specialty fail X reasons AIDS to drug the full and the as to diarrhea activities from a and on cancer patients of from for a perspective. these care regulatory a suffering Crofelemer Hence, much Mytesi clinical therapy. risk the we the the execution prophylaxis and people
preventing focus expected In on the a pleased in Advisory patient in joined Scientific States. she for patients a advocacy Dr. and Crofelemer a to of cancer for the patient in our advocate, both and commercial accurative importance care of Shanahan, commitment cancer Kelly of our patient clinician is shares who the preparation in comfort full-time especially ameliorating general. patient by chronic initiatives both in goal, metastatic we're and breast basis dignity, now Jaguar herself and support and metastatic CTD deep has independent United increasing cancer to patients, a to care CTD, supportive this provider In we're Board very the a launch former And settings. health on as
voice successful to key supportive so management is and care hear cancer outcomes. to treatment a how Shanahan's are pleased We on successful perspective Dr. component
to to unique novel perspective care as industry life bring augment of of welcome potential neglected address community, to support are and for paradigm high the to long-term comfort management support and life. unmet community comorbidity holistic will She and shift targeted full CTD quality to including a approach a and the our patient and brings efforts about We that and a addressing support approaches very cures agents cancer.
intestinal and and Crofelemer. Europe, year, I'll Napo the refer diarrheal inclusion now company target with This rare failure planning studies disorder. to pediatric adults proof-of-concept MVID disease ultrarare of Short we are obtaining third with in and including SBS X reduction patients with of prioritized support with Therapeutics, which or I failure proof-of-concept on in for disease, congenital microvillous showing IV party in fluids. support, bowel nutrition Jaguar investigator-initiated data pediatric third-party established syndrome of Crofelemer intestinal our parenteral SBS as indications an discuss focused we requirements MVID, supporting parenteral patients and/or to are
from the access well. while Spain patient with in or access Italy, early for support full the in States, exist publications guidelines in these countries, programs development approval revenue accordance patients reimbursable potentially indicated as participating intestinal the for SBS do to In clinical Early is France, specific of product are programs proof-of-concept certain not MVID with European United continuing trials failure could European the in through generating U.K., XXXX and programs EU. perhaps for of Union through data Crofelemer countries,
for a for syndrome. the result X in moment a XX situation short an surgery short as XX syndrome, feet be for bowel people to or or describe reasons me of feet patient's could inflammation length. small the is Normal bowel with less due catastrophic medical than cancer congenital intestine accident. to In Let bowel small
not a minerals. you line and nutrients very real for What comes can bottom estate, right intestinal of in it's SBS the fats, life, imagine, SIV enough absorb there's protein, gut, out; like to vitamins enough As with patient goes the [ph]. surface the area short carbohydrate, is,
associated XX nutrients a Obviously, liquid patients that the days patients' of a a $X this thousands complications have failure, week. up patient of to nutrition is up and including quite associated significant nutrition, there common. And SBS other million individual on a the high to hundreds expensive, end costing morbidity, what parenteral parenteral X on day, parenteral are hours intravenous such and of nutrition complications mortality. multiple quality feeding adverse events, So manage has often year negative with to for infections an myriad is high with impact happens of life intestinal that
an The Research global projected the indication disease to a orphan is business Vision again, patients reach XXXX, around world billion model. [ph] orphan from rare reports. SBS this, classic market to but we're reports And XX,XXX of according $X by about
parental care, GLP-X there's for is absorption SBS the administered injection approved be growth to a population. not so and of of a little bit less hormone, a gut the in an is call and there utilized It's the than more is Although as is product intended considered the standard drug estate standard real the essentially of slightly, It's of its for analog. XX% Nutrition time Teduglutide of nutrient estimated it life. Again, care. to SBS grow
the Teduglutide including not time do patients Crofelemer parenteral the endpoint situation. we're point tolerated better and in hard the well as was looking What liver for stool range reduction required which a time the be in Teduglutide by is a the been as to of end on trial nutrition pronounce, effects, to on is quality many disorders has approval is primary of the has utilized life The and the teduglutide parenteral chronic already provide side reduce of XX%. nutrition that measurement. on consistency and by to to primary about with pathway
of is Crofelemer FDA investigation and bowel in to are agency and Phase which syndrome with the application another an XXXX. study of European Medicines around of also Jaguar of just the drug We regulatory the II the to design MVID to the milestone corner. that is the new for IND the FDA a of requirements Agency, submit quarter working second both Again, harmonizes EU. planning global short EMA the
certain time OnTarget XXXX, a a our couple targeting within primary QX, get of completion just have of QX MVID the with expect into enrollment process days only pathway indications. on either and/or the in in This we're disease for participation and III of with literally, meaningful That's intestinal participation, bring Phase first Crofelemer basis could cancer rare proof-of-concept therapy-related patients endpoint in to evidence of European failure these program early the through support revenue-generating X to recap, continues expected for same potential in our in full global readout trial to this prophylaxis year SBS to access of a for go in not away, for So early while EU approval, of we revenues the with in trial diarrhea. countries. frame, QX
at this to other development discuss our going stage I'm now programs time.
the either. key be late-stage for for for the to recognition with these particularly transformative prioritizing in clinical conditions XXXX, companies programs are We has X with Jaguar, spared value development current near-term with market Jaguar which milestones potential financial emerging biotech not
current solution. And a milestones. clinical to our to new one recap, $XX.X relevant important these million, cash achieving
hand let page Events be in to submitted our to link Questions participating I today jaguar.health. at writing of and have appears any website can Jaguar's a the anybody webcast know I time over the that Presentations on the Relations section to submitted we are end want for Jaguar's CFO, of and the if will for. website. Carol Q&A is that brief we discussion you via address URL event the of there Before today's questions The for webcast Lizak. segment that have the that Investor
move We the to along you. XXXX. Lizak, me will key hand quarter results it Carol fourth financial now of let over And to for
